In vitro contact phase activation with haemodialysis membranes: role of pharmaceutical agents.
Contact phase activation was investigated in vitro using flat sheet type of haemodialysis membranes, Cuprophan (Akzo, Faser, Germany) and AN69S (Hospal, France), and a negatively charged polyamide Ultipor NR 14225 membrane as a control. The investigation focussed on the determination of factor XII-like activity (FXIIA) as an indicator of contact phase activation in the supernatant phase and at the membrane surface after plasma-membrane contact using an incubation test cell. The findings were compared with the observations from a plasma-free system utilizing purified unactivated factor XII. The plasma FXIIA bound to the membrane surface was significantly different between the membranes, while the supernatant phase FXIIA exhibited no significant differences. In contrast, the plasma-free system exhibited significant differences in the supernatant FXIIA and membrane-bound FXIIA for all the materials used and the magnitude of the activity was significantly greater for negatively charged materials. This finding demonstrated the strong influence of the interaction of other plasma constituents on the membrane surface and as such the binding and subsequent activation of factor XII may be altered possibly due to competitive binding and steric hindrance. On the addition of anticoagulants such as heparin, low-molecular-weight heparin, citrate and hirudin, no significant differences were observed in plasma supernatant phase FXIIA. However, each anticoagulant appears to have a distinct influence on the magnitude of plasma membrane-bound FXIIA. On the addition of aprotinin (a kallikrein inhibitor), no significant differences were observed in the plasma supernatant FXIIA. In contrast, aprotinin appears to significantly reduce membrane-bound FXIIA on Cuprophan and polyamide NR, but significantly increase the magnitude of the membrane-bound FXIIA on AN69S.
Matata
B M
BM
Bioengineering Unit, University of Strathclyde, Wolfson Centre, Glasgow, UK.
Wark
S
S
Sundaram
S
S
Courtney
J M
JM
Gaylor
J D
JD
Bowry
S K
SK
Vienken
J
J
Lowe
G D
GD
D000925:Anticoagulants / Q000494:pharmacology*; D007611:Aprotinin / Q000494:pharmacology; D001667:Binding, Competitive / Q000187:drug effects; D002482:Cellulose / Q000031:analogs & derivatives / Q000737:chemistry / Q000378:metabolism; D002951:Citrates / Q000494:pharmacology; D019343:Citric Acid; D017985:Dalteparin / Q000494:pharmacology; D005174:Factor XII / Q000378:metabolism* / Q000494:pharmacology; D005343:Fibrinolytic Agents / Q000494:pharmacology*; D006490:Hemostatics / Q000494:pharmacology; D006493:Heparin / Q000494:pharmacology; D006629:Hirudins / Q000494:pharmacology; D066298:In Vitro Techniques; D008567:Membranes, Artificial; D008970:Molecular Weight; D009757:Nylons / Q000737:chemistry / Q000378:metabolism; D011994:Recombinant Proteins / Q000494:pharmacology; D006435:Renal Dialysis; D013499:Surface Properties
D000925:Anticoagulants; D002951:Citrates; D005343:Fibrinolytic Agents; D006490:Hemostatics; D006629:Hirudins; D008567:Membranes, Artificial; D009757:Nylons; D011994:Recombinant Proteins; D019343:Citric Acid; D005174:Factor XII; D002482:Cellulose; D006493:Heparin; C009865:cuprammonium cellulose; D007611:Aprotinin; D017985:Dalteparin